This is a summary of the European public assessment report (EPAR) for Cuprior. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Cuprior. For practical information about using Cuprior, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ? 5 years intolerant to D-penicillamine therapy.
Therapeutic Area (MeSH)
N/AATC Code
A16AX
ATC Item
各种消化道产物及代谢产物
Pharmacotherapeutic Group
Other alimentary tract and metabolism products
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| trientine tetrahydrochloride | N/A | Trientine tetrahydrochloride |
| Trientine tetrahydrochloride | N/A | Trientine tetrahydrochloride |
EMA Name
Cuprior
Medicine Name
Cuprior
Aliases
N/ANo risk management plan link.
